Vamsi Kota, MD
Hematology & Oncology · Augusta, GANPI 1790902393
Payments from drug & device makers
Across 255 payments — averaging $6020.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$533K
- Takeda Pharmaceuticals U.S.A., Inc.$525K
- Incyte Corporation$226K
- Amgen$67K
- Astellas Pharma Global Development$48K
- Novartis$42K
- plus $95K from 14 others
Across 32 payments — averaging $1620.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$30K
- Novartis$22K
- F. Hoffmann-la Roche AG$480
What the payments were for
- Consulting fees$68,07775%
- Speaking & faculty fees$17,47519%
- Travel & lodging$3,0293%
- Food & beverage$2,7023%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $532,978 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $524,554 |
| Incyte Corporation | 55 | $226,218 |
| Amgen | 2 | $66,780 |
| Astellas Pharma Global Development | 6 | $47,926 |
| Novartis | 46 | $42,016 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26,717 |
| Sanofi US Services Inc. | 17 | $23,413 |
| Iovance Biotherapeutics, Inc. | 4 | $13,854 |
| Servier Pharmaceuticals LLC | 7 | $10,091 |
| Macrogenics, Inc. | 4 | $9,494 |
| Gilead | 11 | $9,431 |
| Bristol Myers Squibb | 3 | $900 |
| Apellis Pharmaceuticals, Inc. | 3 | $275 |
| Karyopharm Therapeutics Inc. | 2 | $196 |
| Sanofi-aventis U.S. LLC | 1 | $121 |
| Kadmon Corporation LLC | 1 | $96 |
| Janssen Scientific Affairs, LLC | 2 | $88 |
| Epizyme, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,535,178 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 21 | $48,375 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $424 |
| Oxycodone Hcl | 29 | $334 |
| Acyclovir | 15 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Augusta
- Abdullah KutlarAugusta$2.9M
- Jigarkumar ParikhAugusta$2.1M
- Asha NayakAugusta$1.2M
- Amany KeruakousAugusta$708K
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.